with Tom Still

Reach of angel, venture capital extends beyond portfolio companies

(page 1 of 2)

Most people think of venture capital as a big-city sport, with East and West Coast metros standing out as major-league players. Mid-sized cities such as Madison and Milwaukee are emerging targets for venture capital investment, but they’re still seen as competing for smaller pools of dollars.

The rest of the country, including much of Wisconsin, lies largely outside the venture economy — or does it?

The story of NeuWave Medical, a medical therapy company that grew out of UW–Madison research before it was acquired by a global health care firm, shows how venture and angel capital often flows to suppliers and other businesses throughout the economy.

Scott Button, managing director of Venture Investors LLC, recounted the NeuWave deal at an Oct. 11 meeting of the Tech Council Innovation Network in Appleton. It was a case study of how young, venture-backed companies grow — and it also illustrated how angel and venture capital dollars spread across the economy.

NeuWave was acquired by Ethicon, a division of Johnson & Johnson, in 2016 following a 12-year journey from idea to U.S. Food and Drug Administration clearance to widespread medical use. At the time it was acquired, NeuWave’s tumor-destroying system had been used to treat nearly 14,000 patients in 272 medical centers. The company had 114 employees in 2016, of whom almost all have remained in Wisconsin.

The core process is “tumor ablation,” which uses high-energy microwaves to precisely remove cancer in human livers. The doctor inserts a thin, needle-like probe into the tumor. A high-frequency current is then passed through the tip of the probe or probes, which heats the tumor and destroys the cancer cells.

Traditional liver surgeries for such tumors can lead to high blood loss, longer hospital stays, and occasional deaths. Tumor ablation is often a same-day procedure with better outcomes, faster recovery, and less cost.

It was developed through a collaboration between physician-scientists and engineers at the UW–Madison, with researchers Fred Lee and Dan van der Weide leading the way and starting a precursor company, Micrablate, in 2004. By 2008, Venture Investors was involved as a lead investor and eventually metered about $12 million into the company, which raised about $54 million over time.

Some of that money went into developing components of the NeuWave system, such as a high-pressure cooling system, an electromechanical cart, an electronic enclosure, and a power delivery module through Wisconsin companies such as Sani-Matic, MPE Mobility Systems, Allied Panels, and Plexus. Materials for the probe, as well as assembly and testing, were also sourced almost entirely in Wisconsin.

As Button explained, that’s not unusual for portfolio companies financed by Venture Investors. “Often, that money stays pretty close to home,” he said.